CagriSema Treatment

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

The filing positions a potential 2026 FDA review for what could be the first fixed‑dose GLP‑1 and amylin combination therapy.